Management of dyspnea in advanced lung cancer: Recent data and emerging concepts

Current Opinion in Supportive and Palliative Care

Volumn 4, Issue 2, 2010, Pages 85-91

  Xue, Dong ^a   Abernethy, Amy P ^b  

^a PEKING UNIVERSITY   (China)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breathlessness; Dyspnea; Lung cancer; Palliative care; Quality of life

Indexed keywords

BREATHING EXERCISE; DYSPNEA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; OXYGEN THERAPY; PALLIATIVE THERAPY; QUALITY OF LIFE; REVIEW;

BREATHING EXERCISES; CARCINOMA, NON-SMALL-CELL LUNG; DYSPNEA; HUMANS; LUNG NEOPLASMS; OXYGEN INHALATION THERAPY; PALLIATIVE CARE; QUALITY OF LIFE;

EID: 77953820265     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328339920d     Document Type: Review

References (58)

1. NCCN clinical practice guidelines in oncology: non-small cell lung cancer V.2. 2009. www.nccn.org. [Accessed 15 November 2009].
2. Horner MJ, Ries LAG, Krapcho M, et al. SEER cancer statistics review, 1975-2006. Bethesda, Maryland: National Cancer Institute. http://seer.cancer. gov/csr/1975-2006/ (based on November 2008 SEER data submission, posted to the SEER website, 2009).
3. Reddy SK, Parsons HA, Elsayem A, et al. Characteristics and correlates of dyspnea in patients with advanced cancer. J Palliat Med 2009; 12:29-36.
4. Mohan A, Singh P, Kumar S, et al. Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced nonsmall cell lung cancer. Asian Pac J Cancer Prev 2008; 9: 557-562.
5. Henoch I, Bergman B, Gustafsson M, et al. Dyspnea experience in patients with lung cancer in palliative care. Eur J Oncol Nurs 2008; 12:86-96.
6. LeGrand SB, Walsh D. Palliative management of dyspnea in advanced cancer. Curr Opin Oncol 1999; 11:250-254.
7. Sen E, Kaya A, Erol S, et al. Lung cancer in women: clinical features and factors related to survival. Tuberk Toraks 2008; 56:266-274.
8. Gupta D, Lis CG, Grutsch JF. The relationship between dyspnea and patient satisfaction with quality of life in advanced cancer. Support Care Cancer 2007; 15:533-538. (Pubitemid 46570782)
9. Lai YL, Chan CW, Lopez V. Perceptions of dyspnea and helpful interventions during the advanced stage of lung cancer: Chinese patients' perspectives. Cancer Nurs 2007; 30:E1-8.
10. Abernethy AP, Uronis HE, Wheeler JL, Currow DC. Pharmacological management of breathlessness in advanced disease. Progress Palliat Care 2008; 16:15-20.
11. Bausewein C, Farquhar M, Booth S, et al. Measurement of breathlessness in advanced disease: a systematic review. Respir Med 2007; 101:399-410.
12. Movsas B, Moughan J, Sarna L, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol 2009; 27:5816-5822.
13. Currow DC, Agar M, Smith J, Abernethy AP. Does palliative home oxygen improve dyspnoea? A consecutive cohort study. Palliat Med 2009; 23:309-316.
14. Uronis HE, Blackwell S, Abernethy AP, et al. An examination of the psychometric properties of an English version of the Cancer Dyspnea Scale (CDS) for evaluating dyspnea in patients with advanced lung cancer. In:Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology Annual Symposium; 28 June 2007; St Gallen, Switzerland.
15. Dorman S, Jolley C, Abernethy A, et al. Researching breathlessness in palliative care: consensus statement of the National Cancer Research Institute Palliative Care Breathlessness Subgroup. Palliat Med 2009; 23:213-227; Epub 2009 Feb 27.
16. Salvo N, Hadi S, Napolskikh J, et al. Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review. Curr Oncol 2009; 16:16-28.
17. Henoch I, Bergman B, Danielson E. Dyspnea experience and management strategies in patients with lung cancer. Psychooncology 2008; 17:709-715.
18. Cheung WY, Le LW, Zimmermann C. Symptom clusters in patients with advanced cancers. Support Care Cancer 2009; 17:1223-1230; Epub 2009 Jan 30.
19. Abernethy AP, Wheeler JL. Total dyspnoea. Curr Opin Support Palliat Care 2008; 2:110-113.
20. Demmy TL, Nwogu C. Is video-assisted thoracic surgery lobectomy better? Quality of life considerations. Ann Thorac Surg 2008; 85:S719-S728.
21. Grønberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced nonsmall-cell lung cancer. J Clin Oncol 2009; 27:3217-3224; Epub 2009 May 11.
22. Helbekkmo N, Strøm HH, Sundstrøm SH, et al., Norwegian Lung Cancer Study Group. Chemotherapy and quality of life in NSCLC PS 2 patients. Acta Oncol 2009; 48:1019-1025.
23. Shepherd FA, Rodrigues Pereira J, Tan EH, et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 2005; 353:123-132.
24. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 24:3831-3837.
25. Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-smallcell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26:2350-2357.
26. Quentin C, Coens C, Maver M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009; 10:865-871.
27. Xu ZY, Jin CJ, Shen DY. Clinical study on treatment of advanced nonsmall-cell lung cancer with Chinese herbal medicine in different stages combined with chemotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007; 27:874-878.
28. Rolski J, Zemełka T, Jasio'wka M, et al. Chemotherapy of advanced non small cell lung cancer: effect on survival and symptoms affecting quality of life. Pneumonol Alergol Pol 2007; 75:343-348.
29. Russo F, Bearz A, Pampaloni G, Investigators of Italian Pemetrexed Monotherapy of NSCLC Group. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic nonsmall cell lung cancer. BMC Cancer 2008; 8:216.
30. William WN Jr, Khuri FR, Fossella FV, et al. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol 2010; 33:148-152.
31. Lilenbaum R, Raez L, Tseng J, et al. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced nonsmall cell lung cancer. J Thorac Oncol 2008; 3:511-515.
32. Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOGstudy N0426. J Clin Oncol 2010; 28:614-619.
33. Chiappori AA, Haura E, Rodriguez FA, et al. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced nonsmall cell lung cancer. Clin Cancer Res 2008; 14:1464-1469.
34. Scagliotti GV, GermonpréP, Bosquée L, et al. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2009 [Epub ahead of print].
35. West HL, Wakelee HA, Perry MC, et al. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced nonsmall-cell lung cancer: a phase II clinical trial. Ann Oncol 2009; 20:850-856; Epub 2009 Jan 15.
36. Lamont EB, Herndon JE 2nd, Weeks JC, et al. Cancer and Leukemia Group B. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care 2008; 46:303-308.
37. Rosenzweig KE, Movsas B, Bradley J, et al. ACR appropriateness criteria on nonsurgical treatment for nonsmall-cell lung cancer: poor performance status or palliative intent. J Am Coll Radiol 2009; 6:85-95.
38. Skowronek J, Kubaszewska M, Kanikowski M, et al. HDR endobronchial brachytherapy (HDRBT) in the management of advanced lung cancer: comparison of two different dose schedules. Radiother Oncol 2009; 93:436-440.
39. Scarda A, Confalonieri M, Baghiris C, et al. Out-patient high-dose-rate endobronchial brachytherapy for palliation of lung cancer: an observational study. Monaldi Arch Chest Dis 2007; 67:128-134.
40. Mallick I, Sharma SC, Behera D, et al. Optimization of dose and fractionation of endobronchial brachytherapy with or without external radiation in the palliative management of nonsmall cell lung cancer: a prospective randomized study. J Cancer Res Ther 2006; 2:119-125.
41. De Ruysscher D, Dehing C, Yu S, et al. Dyspnea evolution after high-dose radiotherapy in patients with nonsmall cell lung cancer. Radiother Oncol 2009; 91:353-359.
42. Borst GR, Belderbos J, Burgers S, et al. Dyspnea evolution after high-dose radiotherapy in patients with nonsmall cell lung cancer. Radiother Oncol 2009; 91:461; author reply 461-462
43. Cherny NI, Abernethy AP, Strasser F, et al. Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. J Clin Oncol 2009; 27:5476-5486.
44. NCCN clinical practice guidelines in oncology: palliative care V.1. 2009. www.nccn.org. [Accessed 15 November 2009].
45. Lorenz KA, Lynn J, Dy SM, et al. Evidence for improving palliative care at the end of life: a systematic review. Ann Intern Med 2008; 148:147-159.
46. Currow DC, Ward AM, Abernethy AP. Advances in the pharmacological management of breathlessness. Curr Opin Support Palliat Care 2009; 3:103-106.
47. Currow DC, Abernethy AP. Pharmacological management of dyspnoea. Curr Opin Support Palliat Care 2007; 1:96-101.
48. Gauna AA, Kang SK, Triano ML, et al. Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: an observational case series. J Palliat Med 2008; 11:643-648.
49. Wilcock A, Walton A, Manderson C, et al. Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. Thorax 2008; 63:872-875.
50. Bausewein C, Booth S, Gysels M, Higginson I. Nonpharmacological interventions for breathlessness in advanced stages of malignant and nonmalignant diseases. Cochrane Database Syst Rev 2008. Apr 16; 2:CD005623.
51. Zhao I, Yates P. Nonpharmacological interventions for breathlessness management in patients with lung cancer: a systematic review. Palliat Med 2008; 22:693-701.
52. Vickers AJ, Feinstein MB, Deng GE, Cassileth BR. Acupuncture for dyspnea in advanced cancer: a randomized, placebo-controlled pilot trial. BMC Palliat Care 2005; 4:5.
53. Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 2006; 54:1-9; Epub 2006 Aug 7.
54. Neragi-Miandoab S. Surgical and other invasive approaches to recurrent pleural effusion with malignant etiology. Support Care Cancer 2008; 16:1323-1331; Epub 2008 Feb 8. Review.
55. Das SC, Chauhan H, Gupta D, et al. Peaceful surrender to death without futile bargaining to live relieves terminal air hunger and anguish. Am J Hosp Palliat Care 2008; 25:496-499.
56. Lee MS, Yang SH, Lee KK, Moon SR. Effects of Qi therapy (external Qigong) on symptoms of advanced cancer: a single case study. Eur J Cancer Care 2005; 14:457-462.
57. Glennon C, Seskevich J. Relaxation technique to ease dyspnea: a tool for oncology nurses. Clin J Oncol Nurs 2008; 12:369-371.
58. NCCN clinical practice guidelines in oncology: non-small cell lung cancer V.1.2010. www.nccn.org . [Accessed 15 November 2009].